TG Therapeutics Inc (TGTX)

Cash ratio

		Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash and cash equivalents	US$ in thousands	92,933	102,304	298,887	553,439	112,637
Short-term investments	US$ in thousands	124,575	59,374	15,876	51,987	27,798
Total current liabilities	US$ in thousands	53,720	53,201	65,384	87,554	84,449
Cash ratio		4.05	3.04	4.81	6.91	1.66

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($92,933K + $124,575K) ÷ $53,720K
= 4.05

The cash ratio of TG Therapeutics Inc has fluctuated over the past five years, ranging from 1.66 in 2019 to 6.91 in 2020.

A higher cash ratio indicates a company's ability to cover its short-term liabilities with its cash and cash equivalents. Therefore, TG Therapeutics Inc's cash ratio has generally been strong, with significant increases in 2020 and 2021, suggesting a healthy liquidity position during those years.

However, the cash ratio decreased in 2022 and 2023, which may indicate a decrease in the company's liquidity position in those years compared to the previous period.

Overall, the company has maintained a relatively healthy cash ratio over the years, but investors and stakeholders should closely monitor the trend to ensure sufficient liquidity for short-term obligations.